creating bispecific antibodies that are essentially fully human, with no engineering required. The method for creating bispecific κλ bodies is simple: a production cell expresses a single heavy ...

Bispecific antibodies combine two therapeutic antibodies into one, simultaneously utilizing the effect of both to benefit patients. However, currently available technologies to produce these two ...

Lonza’s bYlok® technology is changing the way bispecific antibodies are designed. Achieving the correct heterodimerization of light and heavy chains during bispecific production can be challenging, ...

Recent advances in biotechnology have fuelled the development of bispecific antibodies. However, there still remains a number of development challenges for those working in bioprocessing or cell line ...

ImmunoPrecise Antibodies, an AI-driven biotherapeutic research and technology company, has entered into a material transfer ...

UK biotech company Kymab is to collaborate with China’s EpimAb Biotherapeutics to develop bispecific antibodies in the immuno-oncology field. Kymab has developed a next-generation antibody ...

This approval makes the bispecific antibody the first HER2-targeted treatment to carry the indication. Zanidatamab binds two separate regions on the HER2 cell surface protein, crosslinking ...

Merck & Co – known as MSD outside the US and Canada – has entered into an exclusive global licensing agreement worth over $3.2bn to advance LaNova Medicines’ investigational PD-1/VEGF bispecific ...

The follow-on bispecific antibody ATOR-4066 is in preclinical testing. Alligator has a proprietary technology platform, comprised of two antibody libraries, ALLIGATOR-GOLD® and ALLIGATOR-FAB ...